Recursion Pharmaceuticals RXRX
NASDAQ RXRX
$4.11 +0.04 (+1.11%)
As of: Oct 2, 2026 · 11:56 AM EDT

Recursion Pharmaceuticals (RXRX) Preferred Stock Liabilities (2020 - 2021)

Updated

Recursion Pharmaceuticals (RXRX) reported Preferred Stock Liabilities of $448.31 million for Q1 2021, up 122.9% from $201.11 million a year earlier and unchanged from the prior quarter.

Analysis

Recursion Pharmaceuticals (RXRX) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

Dating back to Q1 2020, Recursion Pharmaceuticals' Preferred Stock Liabilities record includes 5 quarters.

  • By year, Preferred Stock Liabilities came in at $201.11 million in FY2019.
  • Per Business Quant data, the three quarters before Q1 2021 came in at $448.31 million (Q4 2020), $437.92 million (Q3 2020) and $201.11 million (Q2 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Recursion Pharmaceuticals 2.21 Bn -397.37 Mn -3.82 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 448.31 Mn
Dec 31, 2020 448.31 Mn
Sep 30, 2020 437.92 Mn
Jun 30, 2020 201.11 Mn
Mar 31, 2020 201.11 Mn
API Access

Recursion Pharmaceuticals Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=RXRX&period=max&api_key=YOUR_API_KEY